Known targets — ChEMBL curated mechanism
CA2CA4GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Topiramate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 20/20 | 1.00 |
| ▸ | CA4 known ✓ | P22748 | 7/20 | 1.00 |
| ▸ | CA1 | P00915 | 10/20 | 1.00 |
| ▸ | CA5A | P35218 | 7/20 | 1.00 |
| ▸ | CA7 | P43166 | 7/20 | 1.00 |
| ▸ | CA9 | Q16790 | 7/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 1.00 |
| ▸ | CA6 | P23280 | 1/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Topiramate SCHEMBL7859335 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL6341452 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL18898593 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL1534094 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL17343471 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL23468160 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL5637335 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL13575742 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL4980190 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 | |
| Topiramate SCHEMBL34631 | 1.00 | CA2 (1.00) | CA2CA1CA4CA5ACA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023049920-A1 | COMBINATION COMPRISING ATOGEPANT FOR TREATING MIGRAINE | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2023-03-30 | — | — | WO | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-3028190-A1 | IDENTIFICATION OF SURGERY CANDIDATES USING NATURAL LANGUAGE PROCESSING | Children's Hospital Medical Center (US) | 2016-06-08 | — | — | EP | disclosed |
| EP-2758053-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | Gilead Sciences, Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043925-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | GILEAD SCIENCES, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| EP-2300027-A1 | METHOD OF TREATING MIGRAINE USING GUAVA | Amerilab Technologies, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2011022292-A2 | METHOD OF TREATING BIPOLAR DISORDER OR DEPRESSION USING AN ANTIESTROGEN | LUNERA RESEARCH, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| WO-2010005438-A1 | METHOD OF TREATING MIGRAINE USING GUAVA | AMERILAB TECHNOLOGIES, INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-7560459-B2 | Substituted sulfamate anticonvulsant derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-14 | — | — | US | disclosed |
| US-20080207601-A1 | Methods of and Compositions For the Prevention of Anxiety, Substance Abuse, and Dependence | HYTHIAM , INC. (US) | 2008-08-28 | — | — | US | disclosed |
| EP-1758600-A4 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MAN SCIENCES LLC (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1868593-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | Hythiam, Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1758600-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | Mood Management Sciences, LLC (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006110642-A2 | IMPROVED METHODS OF AND COMPOSITIONS FOR THE PREVENTION OF ANXIETY, SUBSTANCE ABUSE, AND DEPENDENCE | HYTHIAM, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060058373-A1 | Novel substituted sulfamate anticonvulsant derivatives | ABDEL-MAGID AHMED | 2006-03-16 | — | — | US | disclosed |
| WO-2005120523-A1 | METHODS AND COMPOSITIONS FOR TREATING MOOD DISORDER | MOOD MANAGEMENT SCIENCES, LLC (US) | 2005-12-22 | — | — | WO | disclosed |
| US-5952187-A | ANTIEPILEPTIC AGENT ANALOG DERIVATIZED AT THE SULFAMATE MOIETY OR THE 9-CARBON METHYL GROUP TO ADD LABEL FOR USE IN IMMUNOASSAYS OR TO ADD CARRIER FOR USE AS IMMUNOGEN; FOR MONITORING SERUM OR PLASMA LEVELS OF DRUG | OXIS INTERNATIONAL, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0876385-A1 | TOPIRAMATE IMMUNOASSAY, AS WELL AS ANALOGS AND ANTIBODIES | Oxis International, Inc. (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997019950-A1 | TOPIRAMATE IMMUNOASSAY, AS WELL AS ANALOGS AND ANTIBODIES | OXIS INTERNATIONAL, INC. (US) | 1997-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058373-A1 | Novel substituted sulfamate anticonvulsant derivatives | SULT1E1, CACNA1A, SULT2A1 | CA2 326/4885CA4 581/4885CA1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.